This RYR blockade is believed to contribute to its particular efficacy in CPVT (catecholaminergic polymorphic ventricular tachycardia), most commonly caused by mutations in the RYR [26]. The gene discussed is RYR2; the disease is catecholaminergic polymorphic ventricular tachycardia.